DaVita Inc
NYSE:DVA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
DaVita Inc
Cash Equivalents
DaVita Inc
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
DaVita Inc
NYSE:DVA
|
Cash Equivalents
$676.4m
|
CAGR 3-Years
40%
|
CAGR 5-Years
16%
|
CAGR 10-Years
-8%
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Cash Equivalents
$393m
|
CAGR 3-Years
31%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
12%
|
|
|
CVS Health Corp
NYSE:CVS
|
Cash Equivalents
$8.5B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
1%
|
CAGR 10-Years
13%
|
|
|
Cigna Corp
NYSE:CI
|
Cash Equivalents
$7.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
15%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Cash Equivalents
$532.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-3%
|
|
|
Guardant Health Inc
NASDAQ:GH
|
Cash Equivalents
$378.2m
|
CAGR 3-Years
39%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
DaVita Inc
Glance View
In the intricate network of healthcare services, DaVita Inc. stands as a pivotal player, focusing on the often-overlooked but critical field of kidney care. Rooted in its mission to improve patients' quality of life by innovating kidney care therapies, DaVita has cultivated a robust operation primarily revolving around dialysis services. Chronic Kidney Disease (CKD) and kidney failure are rising global health concerns, necessitating regular dialysis treatments for affected individuals. DaVita serves this need through a network of dialysis centers, offering both in-center and at-home dialysis options. By prioritizing patient comfort and convenience alongside medical efficiency, DaVita has positioned itself as a go-to choice for those requiring ongoing renal care, effectively making the process as seamless as possible for patients. The business model of DaVita hinges on its ability to deliver consistent, high-quality care while managing costs—a balance crucial to success in the healthcare industry. Revenue flows in from both governmental programs such as Medicare and private health insurers, which fund the dialysis treatments for insured patients. DaVita's strategic strength lies in its operational scale, with a vast number of outpatient dialysis centers across the U.S. and internationally. This extensive reach not only strengthens its market position but also provides a wealth of data and feedback, fueling further innovation and efficiency improvements. By leveraging this extensive network, DaVita continues to tap into the growing demand for accessible, comprehensive kidney care services, reinforcing its commitment to patient-centered healthcare delivery while sustaining its financial growth.
See Also
What is DaVita Inc's Cash Equivalents?
Cash Equivalents
676.4m
USD
Based on the financial report for Dec 31, 2025, DaVita Inc's Cash Equivalents amounts to 676.4m USD.
What is DaVita Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
-8%
Over the last year, the Cash Equivalents growth was -15%. The average annual Cash Equivalents growth rates for DaVita Inc have been 40% over the past three years , 16% over the past five years , and -8% over the past ten years .